{
    "2018-08-20": [
        [
            {
                "time": "2018-07-31",
                "original_text": "Amgen’s Product Performance in Q2 2018",
                "features": {
                    "keywords": [
                        "Amgen",
                        "product performance",
                        "Q2 2018"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-01",
                "original_text": "Drugmakers Extend Summer Rally as Markets Regain Footing",
                "features": {
                    "keywords": [
                        "drugmakers",
                        "summer rally",
                        "markets regain footing"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-31",
                "original_text": "Allergan’s US General Medicines Segment in Q2 2018",
                "features": {
                    "keywords": [
                        "Allergan",
                        "US general medicines",
                        "Q2 2018"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-08-02",
                "original_text": "Non-Opioid Pain Therapy Market Opportunity for Teva",
                "features": {
                    "keywords": [
                        "non-opioid pain therapy",
                        "market opportunity",
                        "Teva"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}